# A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

> **NCT00566449** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 32 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-31001074
- **DRUG:** JNJ-31001074

## Key facts

- **NCT ID:** NCT00566449
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566449, "A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00566449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*